Menu
Not yet recruiting NCT06546059

Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy

No phase Interventional Vitiligo, Generalized

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: narrow band ultraviolet-B.
Who it may be relevant to
Registry conditions: Vitiligo, Generalized. Basic parameters: 10 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The aim of this study is to: 1. Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls. 2. Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy. 3. Determine whether there is a relationship between Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients.

Detailed description

The aim of this study is to:

1. Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls. 2. Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy. 3. Determine whether there is a relationship between Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients.

Interventions

  • Device narrow band ultraviolet-B
    vitiligo patients will recevie twice sessions per week

Primary outcome measures

  • Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls. [Time frame: three months]
Secondary outcome measures (2)
  • 2- Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy. [Time frame: three months]
  • 3- Determine whether there is a correlation between tissue immunehistochemstry Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients. [Time frame: three months]

Eligibility criteria

Inclusion criteria

  • Patients with stable vitiligo of 6 months duration,
  • Both sex and ages(10-75)

Exclusion criteria

  • pregnancy,
  • lactation,
  • patients under or previous phototherapy,
  • patients on other immunosuppressives,
  • patients receiving topical or systemic therapy like antioxidants and vitamins were kept off treatment for 2 weeks prior to recruitment into the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06546059 · SVU-MED-,4-24,7,871

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗